Multiple prospective clinical trials and real-world studies have confirmed the superiorities of EGFR-TKIs regarding objective response rate (ORR), progression free survival (PFS), overall survival (OS), and quality of life (QoL) when treating late-stage NSCLC patients with EGFR-sensitive mutations compared to conventional platinum-based Chemotherapy [14,15,16,17]. Here, EGFR is linked to non-small cell lung carcinoma.